I-MAK is a team of lawyers, scientists, and health policy and market dynamics experts who advocate for affordable medications,[3] and prioritize public good over private interests in the medicines system.

[3] I-MAK has served in advisory capacities to patient groups, the European Patent Office, UNITAID, the Clinton Foundation, Médecins Sans Frontières/Doctors Without Borders, Gavi the Vaccine Alliance, and the World Health Organization.

[12] In 2021, I-MAK called on the U.S administration and federal agencies to take action to promote competition and advance equity across government and update the patent system in the public's interest.

Citing I-MAK's research and attention to the issue, in December 2021, the United States House Committee on Oversight and Reform released an investigation on drug pricing, finding that pharmaceutical companies engage in abusive patenting practices to extend their monopolies in the United States.

[20][21] I-MAK joined global health advocates in calling for a waiver to the World Trade Organization's TRIPS agreement so that intellectual property did not inhibit manufacturing and access[22] to COVID-19 technologies, emphasizing the amount of public funding that contributed to vaccine and treatment development.